Ultivue Launches UltiMapper Portfolio of Reagents for Tissue Marker Detection and Analysis at High Level of Multiplexing and Throughput, with Seamless Use in Current Immuno-Histochemistry Workflows.

Ultivue has announced today the public launch of its UltiMapper™
portfolio of reagents enabling the highest throughput of whole-slide,
protein biomarker
analysis and spatial detection in tissue, at high level of
multiplexing, using instrumentation and software solutions currently
found in most Immuno-Histochemistry laboratories. With UltiMapper
I/O reagents, Ultivue introduces a fully optimized, ready-to-use
portfolio of kits enabling fast, holistic profiling and characterization
of tumor immuno-oncology markers in Formalin-Fixed, Paraffin-Embedded
(FFPE) samples. Dr. Michael Natan, Ultivue’s Chief Executive Officer,
“We are delighted to be shipping kits to customers who’ve recognized the
enormous value our reagents provide in I/O drug development, and look
forward to a very significant expansion of our I/O portfolio later this
year to meet the demand of immuno-oncology translational and clinical
research labs. Beyond that, Ultivue will expand its offerings to
oncology, inflammation and auto-immune research areas. In addition to UltiMapper
kit reagents, scientists across the world have access, through Ultivue’s
best-in-class Fee for Service laboratory, to highly customizable,
multiplex assays that incorporate any protein of interest or proprietary
marker antibody.”

UltiMapper
reagents and service offerings are powered by Ultivue’s proprietary InSituPlex™
technology which combines DNA-barcoded antibodies with unique,
complementary, fluorescent DNA barcodes, in a single slide staining,
signal amplification, and imaging step assay. Prior to launch, UltiMapper
reagents have been extensively tested by a diverse and representative
set of leading immuno-oncology Pharma, Cancer Research Centers and
Clinical Research Organizations. “Exceptional quality assay,
straightforward implementation, ease of use of both manual and automated
protocols, very relevant content for tumor immuno-profiling and assay
reproducibility, are the most commonly shared comments on our UltiMapper
kits. Early adopters also commented on the unbiased biology analysis,
enabled by whole slide imaging, which supports complex biomarker
analysis beyond a few, limited regions of interest,” says Philippe
Mourere, SVP Commercial Operations.

Ultivue also announces an upcoming webinar
presented on July 18th, 2018, at 11:00 am EDT, in
collaboration with Leica Biosystems and Indica Labs Inc., and entitled
“From Staining to Analysis: End-to-End Application of UltiMapper
Kits for Multiplexed Immuno-Profiling in FFPE Tumor Samples”. During
this 60-minute webinar, attendees will learn about the InSituPlex
technology, the development and validation of UltiMapper
kit reagents, the use of the assays in a highly automated environment,
and the analysis of whole slide images to extract complex information
such as cell counts, marker co-localization and proximity, providing
insights into complex biological questions posed by the tumor
micro-environment.

About UltivueFounded by two core faculty from the Wyss Institute
at Harvard University? David Walt, a world-leading expert in
biomolecular analysis, and Peng Yin, a pioneer in DNA nanotechnology?
Ultivue is a venture-backed company developing reagent-driven solutions
for high-performance biological imaging in situ, combining unlimited
multiplexing at high speed with high spatial resolution. Ultivue’s
proprietary solutions will enable researchers and clinicians to realize
the promise of personalized medicine through better matching of patients
to therapeutic options. The company is launching products and services
that seamlessly integrate into existing workflows for biomarker
discovery, assay validation, and companion diagnostic applications.
Ultivue is based in Cambridge, MA.To learn more, visit www.ultivue.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005795/en/

Leave a Comment